ECSP21015491A - Administración prolongada de lasmiditan por la noche para la prevención de la migraña - Google Patents

Administración prolongada de lasmiditan por la noche para la prevención de la migraña

Info

Publication number
ECSP21015491A
ECSP21015491A ECSENADI202115491A ECDI202115491A ECSP21015491A EC SP21015491 A ECSP21015491 A EC SP21015491A EC SENADI202115491 A ECSENADI202115491 A EC SENADI202115491A EC DI202115491 A ECDI202115491 A EC DI202115491A EC SP21015491 A ECSP21015491 A EC SP21015491A
Authority
EC
Ecuador
Prior art keywords
migraine
prevention
night
meditan
prolonged administration
Prior art date
Application number
ECSENADI202115491A
Other languages
English (en)
Inventor
Gudarz Davar
Kirk Willis Johnson
Robert Russell Conley
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68051892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21015491(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21015491A publication Critical patent/ECSP21015491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere al uso prolongado de lasmiditan por la noche para la prevención de la migraña, particularmente la migraña resistente al tratamiento que se define en el presente documento como migraña refractaria a dos o más esquemas de prevención o tratamiento previos de monoterapia y/o terapia doble.
ECSENADI202115491A 2018-09-04 2021-03-04 Administración prolongada de lasmiditan por la noche para la prevención de la migraña ECSP21015491A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
ECSP21015491A true ECSP21015491A (es) 2021-04-29

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202115491A ECSP21015491A (es) 2018-09-04 2021-03-04 Administración prolongada de lasmiditan por la noche para la prevención de la migraña

Country Status (36)

Country Link
US (1) US12138254B2 (es)
EP (2) EP3846810B1 (es)
JP (2) JP7321256B2 (es)
KR (1) KR102649644B1 (es)
CN (1) CN112638383A (es)
AU (3) AU2019336667B2 (es)
BR (1) BR112021002945A2 (es)
CL (1) CL2021000529A1 (es)
CO (1) CO2021002766A2 (es)
CR (1) CR20210126A (es)
DK (1) DK3846810T3 (es)
DO (1) DOP2021000039A (es)
EA (1) EA202190440A1 (es)
EC (1) ECSP21015491A (es)
ES (1) ES2967665T3 (es)
FI (1) FI3846810T3 (es)
HR (1) HRP20231587T1 (es)
HU (1) HUE064519T2 (es)
IL (1) IL281208B2 (es)
JO (1) JOP20210033B1 (es)
LT (1) LT3846810T (es)
MA (1) MA53551B1 (es)
MD (1) MD3846810T2 (es)
MX (1) MX2021002474A (es)
MY (1) MY199662A (es)
PE (1) PE20211599A1 (es)
PH (1) PH12021550448A1 (es)
PL (1) PL3846810T3 (es)
PT (1) PT3846810T (es)
RS (1) RS64857B1 (es)
SG (1) SG11202101530PA (es)
SI (1) SI3846810T1 (es)
TW (1) TWI826514B (es)
UA (1) UA129587C2 (es)
WO (1) WO2020051137A1 (es)
ZA (1) ZA202100666B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR102448369B1 (ko) 2014-02-05 2022-09-28 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CZ288897A3 (cs) 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
JPH11513666A (ja) 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
BR9711273A (pt) 1996-08-28 1999-08-17 Lilly Co Eli 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
CA2268164A1 (en) 1996-10-08 1998-04-16 Yao-Chang Xu New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
WO2000000487A1 (en) 1998-06-30 2000-01-06 Eli Lilly And Company 5-ht1f agonists
AU1937300A (en) 1998-12-11 2000-06-26 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
WO2000047559A2 (en) 1999-02-10 2000-08-17 Eli Lilly And Company 5-ht1f agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
HUP0200245A2 (en) 1999-02-26 2002-06-29 Lilly Co Eli Furo[3,2-b]pyridines as 5-ht1f agonists and pharmaceutical compositions containing them and their use
WO2002006196A1 (en) 2000-07-13 2002-01-24 Merck Patent Gmbh Chiral compounds i
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
EP1581498A2 (en) 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
ES2388547T3 (es) 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
KR20070094754A (ko) 2004-12-01 2007-09-21 데브젠 엔브이 이온 채널, 특히 Ｋｖ 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US11053214B2 (en) 2016-12-06 2021-07-06 Colucid Pharmaceuticals, Inc. Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
ES2967665T3 (es) 2024-05-03
EA202190440A1 (ru) 2021-06-24
MD3846810T2 (ro) 2024-04-30
TW202033197A (zh) 2020-09-16
CO2021002766A2 (es) 2021-03-19
PL3846810T3 (pl) 2024-03-18
PE20211599A1 (es) 2021-08-18
JOP20210033B1 (ar) 2024-04-18
JOP20210033A1 (ar) 2021-02-25
MA53551B1 (fr) 2023-11-30
ZA202100666B (en) 2024-09-25
JP2023156344A (ja) 2023-10-24
SG11202101530PA (en) 2021-03-30
NZ774400A (en) 2024-03-22
DOP2021000039A (es) 2021-03-31
CR20210126A (es) 2021-04-22
SI3846810T1 (sl) 2023-12-29
CN112638383A (zh) 2021-04-09
BR112021002945A2 (pt) 2021-05-11
US20210338655A1 (en) 2021-11-04
AU2019336667B2 (en) 2022-09-29
IL281208B1 (en) 2024-10-01
JP2021535913A (ja) 2021-12-23
AU2019336667A1 (en) 2021-03-11
EP4279132A3 (en) 2024-03-06
DK3846810T3 (da) 2023-12-04
MY199662A (en) 2023-11-15
US12138254B2 (en) 2024-11-12
IL281208A (en) 2021-04-29
EP3846810A1 (en) 2021-07-14
MX2021002474A (es) 2021-08-24
MA53551A (fr) 2022-01-12
HUE064519T2 (hu) 2024-03-28
LT3846810T (lt) 2024-01-10
UA129587C2 (uk) 2025-06-11
KR102649644B1 (ko) 2024-03-21
FI3846810T3 (fi) 2023-12-15
AU2022291568A1 (en) 2023-02-02
AU2025201479A1 (en) 2025-03-20
WO2020051137A1 (en) 2020-03-12
TWI826514B (zh) 2023-12-21
EP4279132A2 (en) 2023-11-22
JP7543497B2 (ja) 2024-09-02
RS64857B1 (sr) 2023-12-29
EP3846810B1 (en) 2023-10-18
IL281208B2 (en) 2025-02-01
KR20210039419A (ko) 2021-04-09
HRP20231587T1 (hr) 2024-03-15
JP7321256B2 (ja) 2023-08-04
CA3111205A1 (en) 2020-03-12
PH12021550448A1 (en) 2021-09-27
PT3846810T (pt) 2023-12-14
CL2021000529A1 (es) 2021-08-13

Similar Documents

Publication Publication Date Title
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CL2019001292A1 (es) Nuevos derivados de quinolina.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2020000301A1 (es) Nuevos derivados de quinolina.
MX378969B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
DOP2017000268A (es) Metodos y kits para tratar depresion
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EP3843715C0 (en) THERAPY OF HIGH-RISK HUMAN PAPILLOMAVIRUS INFECTIONS